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ApoC-III, a lipoprotein lipase inhibitor and a key regulator of the metabolism of triglyceride-rich
lipoproteins, is mainly synthesized in liver and intestine, but little is known about its expression
in adipocytes. We here show that apoC-III mRNA levels are dramatically induced during adipocyte
differentiation. Among many transcriptional factors involved in adipocyte differentiation, RXRa,
acting alone and not as a heterodimer partner of other nuclear receptors, solely regulates apoC-III
gene expression. These results suggest that apoC-III may play a speciﬁc role in lipid storage and
mobilization in adipocytes, non-lipoprotein-secreting cells, and indicate the functional role of RXRa
during adipocyte differentiation.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hypertriglyceridemia is a major risk factor in cardiovascular
disease [1]. It is apparently caused by a disorder of lipoprotein
metabolism, as it is typically accompanied by a change in the com-
position of apolipoproteins contained in lipoprotein particles. One
of the apolipoproteins, apoC-III, is a 79-amino acid glycoprotein
which is mainly synthesized in the liver and to a lesser extent,
the intestine [2], and is mainly detected in the triglyceride-rich
lipoprotein (TRL) fraction [3]. Plasma apoC-III levels are positively
correlated with plasma triglyceride levels [4]. ApoC-III inhibits
lipoprotein lipase (LPL) activity by interfering with the interaction
between TRLs and LPL, and also preventing apoE-mediated uptake
of TRLs [5], thereby impairing TRL lipolysis. High levels of plasma
apoC-III in apoC-III transgenic mice cause hypertriglyceridemia
[6], whereas the absence of apoC-III leads to the reduced plasma
triglyceride levels, and resistance to diet-induced obesity [7,8]. It
has been reported that apoC-III gene expression in the liver is reg-
ulated by various factors and drugs including insulin, bile acids,
retinoids, statins and ﬁbrates [9–13]. However, little is known
about apoC-III expression in adipose tissue.
In this study, we found that apoC-III mRNA levels are dramati-
cally increased during adipocyte differentiation not only in 3T3-L1
cells, but also in primary preadipocytes and mouse embryonic
ﬁbroblasts (MEFs), and that the transcriptional induction is medi-chemical Societies. Published by E
. Sato).ated by RXRa and its agonists. These results indicate that
apoC-III may have a functional role in mature adipocytes, non-lipo-
protein-secreting cells, and that RXRa directly regulates the
expression of certain genes during the differentiation by a pathway
other than through heterodimerization with other nuclear receptor
family members.
2. Materials and methods
2.1. Antibodies and reagents
Anti-RXRa and PPARc antibodies were purchased from Santa
Cruz. Anti-b-actin was from Sigma. Pioglitazone was a kind gift
from Takeda Chemical Industries. Insulin, dexamethasone, 9-cis
retinoic acid, TTNPB, GW0742 and the protease inhibitor cocktail
were from Sigma. 3-Isobutyl-1-methylxanthine was from Wako.
PA024 was previously described [14]. Taq-Man probes were from
Applied Biosystems.
2.2. Preparation of primary preadipocytes
Fibroblastic primary preadipocytes were isolated from subcuta-
neous fat pads of C57BL/6 mice. The removed fat pads were minced
in Dulbecco’s modiﬁed Eagle’s medium (DMEM). After digestion in
DMEM with 1.0 mg/mL collagenase at 37 C for 1 h in a shaking
water bath, the digest was ﬁltered through a sterile 100 lm nylon
mesh (Falcon) and collected by centrifugation. After being washed
twice, the pellets were resuspended with a medium A (DMEMwithlsevier B.V. All rights reserved.
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streptomycin), and plated on type I collagen-coated 35 mm culture
dishes (Falcon). The media were changed every 2 days until the
cells were subjected to adipocyte differentiation.
2.3. Preparation of MEFs
Primary MEFs isolated as described previously [15] were cul-
tured in a medium A, and passage was discontinued before they
became conﬂuent. Differentiation experiments were carried out
using the cells at passage 2.
2.4. Cell culture
3T3-L1 preadipocytes were differentiated into adipocytes as de-
scribed previously [16]. Primary preadipocytes cultured in mediumA
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Fig. 1. ApoC-III mRNA levels increase during adipocyte differentiation. (A) 3T3-L1
cells, (B) primary preadipocytes or (C) MEFs were differentiated into adipocytes and
total RNA was isolated every 2 days. The mRNA levels of apoC-III and aP2 were
determined by real-time RT-PCR after being normalized to S17 rRNA. Relative
mRNA levels on day 0 were considered as ‘‘1”. (D) Adipocytes and SVCs were
fractionated and their total RNA was isolated. The apoC-III and adiponectin mRNA
levels were determined by real-time RT-PCR after being normalized to 18S rRNA.
Relative mRNA levels in SVC fraction were considered as ‘‘1”. All data represent the
mean ± S.D. of three separate experiments.A were differentiated the same as 3T3-L1 cells were. MEFs were
differentiated into adipocytes as well as 3T3-L1 cells, except for
adding 10 lM pioglitazone in the medium during the
differentiation.
2.5. Adipocyte fractionation
Subcutaneous fat pads isolated from 8-week-old C57BL/6 mice
were minced, and digested using collagenase (1 mg/mL) in KRB
buffer (118.1 mM NaCl, 4.6 mM KCl, 2.5 mM CaCl2, 1.2 mMMgSO4,
32.3 mM HEPES, 2 mM glucose) with 4% BSA at 37 C for 1 h in a
shaking water bath. The digest was ﬁltered through a sterile 100
lm nylon mesh (Falcon) and centrifuged at 2000 rpm for 5 min.
The adipocytes were ﬂoated to the top of the tube, and after being
washed with KRB buffer several times, total RNA was extracted
using ISOGEN-LS (Nippon Gene Co.). The pellets were also washed
with KRB buffer several times, and red blood cells were lysed by
resuspension with erythrocyte lysis buffer (154 mM NH4Cl,
10 mM KHCO3, 1 mM EDTA). After passage through a sterile0
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Fig. 2. RXRa ligands induce apoC-III expression in adipocytes. (A and B) 3T3-L1
cells 5 days after being differentiated into adipocytes were treated with either 1 lM
9-cis RA, 10 lM pioglitazone, 1 lM T0901317, 2 lM TTNPB or 10 lM GW0742 (A),
1 lM 9-cis RA or 2 lM PA024 (B) for 12 h. The mRNA level of apoC-III was
determined by real-time RT-PCR after being normalized to S17 rRNA. (C) Primary
preadipocytes were differentiated into adipocytes, and after 4 days of differenti-
ation, the cells were treated with 1 lM 9-cis RA or 2 lM PA024 for 12 h. The mRNA
level of apoC-III was determined by real-time RT-PCR after being normalized to S17
rRNA. All values are comparable to control ones considered as ‘‘1”. All data
represent the mean ± S.D. of three separate experiments. *P < 0.05; **P < 0.01.
Y. Takahashi et al. / FEBS Letters 583 (2009) 493–497 49530 lm nylon mesh, the total RNA of stromal-vascular cells (SVCs)
was extracted using RNeasy Mini Kit (QIAGEN).
2.6. Plasmids
Expression plasmid for RXRawas generated by inserting its PCR
products into pCMV5 or p3xFLAG-CMV (Sigma) and then veriﬁed
by sequencing. The expression was conﬁrmed by western blot
analysis.
2.7. Real-time RT-PCR
Total cellular RNA was extracted by using an RNA preparation
kit (RNeasy Mini Kit, QIAGEN), and then reverse transcription
was performed using High-Capacity cDNA Reverse Transcription
Kits (Applied Biosystems). Fluorescence real-time PCR was per-
formed as described previously [17].
2.8. Western blot analysis and reporter assays
Western blot analysis and reporter assays were carried out as
previously described [17].
2.9. Chromatin immunoprecipitation (ChIP) assay
3T3-L1 adipocytes were subjected to ChIP assay as described
previously [17]. Semi-quantitative PCR was performed with the
following primers: apoC-III forward (50-GCCTGTCACTGGCTC-
TAGGCTG-30), apoC-III reverse (50-TCCAGACCAGAGCCTGAGGCAG-
30). The primers generate a 210-bp fragment of apoC-III promoter.
Fluorescence real-time PCR was performed with the following
primers: apoC-III forward (50-TCACTAATCCCTGCCCAGCTA-30),0
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Fig. 3. RXRa regulates the apoC-III promoter activities in 3T3-L1 cells. (A) 3T3-L1 pread
+546) with or without an expression plasmid for RXRa and together with pCMV-b-gal.
concentration of 9-cis RA for a further 24 h. The luciferase activities were measured and
RXRa expression plasmids and 9-cis RA are represented as ‘‘1”. (B) 3T3-L1 preadipocyte
versions of the reporter plasmid with apoC-III promoter together with pCMV-b-gal. After
additional 24 h. (C) The sequence around the DR-1 element is shown in the mouse apoC-
for RXRa and a reporter plasmid with apoC-III-1500 or ApoC-III-1500-del together with
1 lM 9-cis RA for a further 24 h. All data represent the mean ± S.D. of three separate exapoC-III reverse (50-AAGGTTACATGCCCCCACACT-30). The primers
generate a 80-bp fragment of apoC-III promoter.
3. Results and discussion
In the course of the screening of genes highly induced during
adipocyte differentiation in 3T3-L1 cells, we found that the mRNA
levels of apoC-III were drastically increased in the course of differ-
entiation (Fig. 1A). The mRNA levels of aP2, an adipocyte differen-
tiation marker, were also increased. Next, we prepared primary
preadipocytes from C57BL/6 mice, and the cells were differentiated
into adipocytes. The results demonstrate that the mRNA levels of
apoC-III, as well as aP2, were increased during the differentiation
process (Fig. 1B). Induction of apoC-III mRNA was also conﬁrmed
in differentiated adipocytes of MEF and OP9 cells (Fig. 1C and data
not shown). Furthermore, we fractionated adipocytes from SVCs in
white adipose tissue of C57BL/6 mice, and examined whether
apoC-III is exclusively expressed in adipocytes. The mRNA levels
of adiponectin, an adipocytokine highly expressed in adipocytes
[18], were over a hundred fold higher in the adipose fraction than
in the SVC fraction (Fig. 1D). ApoC-III mRNA was also highly recov-
ered in the adipose fraction (Fig. 1D), indicating that apoC-III is
exclusively expressed in adipocytes.
Next, we investigated the mechanism for the regulation of
apoC-III gene expression. The differentiated 3T3-L1 cells were trea-
ted with various ligands of nuclear receptors expressed in adipo-
cytes. All the agonists for PPARc (pioglitazone), LXR (T0901317),
RAR (TTNPB), and PPARd (GW0742), failed to increase the apoC-
III mRNA levels (Fig. 2A). Only the RXR agonist 9-cis RA increased
the mRNA levels approximately 2.5-fold (Fig. 2A). 9-Cis RA, a natu-
ral ligand for both RAR and RXR, activates not only the RAR-RXR
heterodimer, but also the RXR homodimer, which binds the con-Fold induction by RXRα
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After 24 h of transfection, the cells were refed with media containing the indicated
normalized to b-galactosidase activities. The promoter activities in the absence of
s were transfected with an expression plasmid for RXRa and one of the truncated
24 h of transfection, the cells were refed with media containing 1 lM 9-cis RA for an
III promoter. (D) 3T3-L1 preadipocytes were transfected with an expression plasmid
pCMV-b-gal. After 24 h of transfection, the cells were refed with media containing
periments. **P < 0.01.
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agonist PA024 also elevated the apoC-III mRNA levels (Fig. 2B).
The same results were obtained in primary preadipocytes; i.e. both
9-cis RA and PA024 induced apoC-III gene expression, whereas
pioglitazone did not (Fig. 2C).
Reporter gene assays with the apoC-III promoter were per-
formed. The forced expression of RXRa together with treatment
with its ligand activated the apoC-III promoter activity in 3T3-L1
cells (Fig. 3A). Reporter assays using several truncated versions of
reporter plasmids revealed that the promoter activities were
greatly reduced between pApoC-III-900 and pApoC-III-1100A
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Fig. 4. Endogenous RXRa binds to the apoC-III promoter in adipocytes. (A) 3T3-L1
cells were differentiated into adipocytes and harvested on the indicated days, and
whole cell lysates were subjected to SDS–PAGE andWestern blot analysis with anti-
RXRa, PPARc and b-actin antibodies. (B) 3T3-L1 cells 4 days after being differen-
tiated into adipocytes were treated with 1 lM 9-cis RA for 6 h. Then the cells were
harvested and immunoprecipitation with anti-RXRa antibody was carried out.
Fragmented soluble chromatin immunoprecipitates were evaluated by semi-
quantitative PCR (upper) or quantitative real-time PCR (lower) with speciﬁc
primers for the mouse apoC-III promoter. Quantitative real-time PCR was
performed in duplicate and the data represent the mean ± S.D. **P < 0.01.
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Fig. 5. Expression of apoC-III in tissues. Total RNA was isolated from liver, intestine,
subcutaneous fat and epididymal fat from a C57BL/6 mouse. The relative mRNA
levels of apoC-III were determined by real-time RT-PCR after being normalized to
S17 rRNA. Real-time RT-PCR was performed in triplicate and the data represent the
mean ± S.D.(Fig. 3B). In this region a DR-1-like sequence was identiﬁed to
which an RXRa homodimer bound, as shown in Fig. 3C. When this
region was deleted from pApoC-III-1500 (pApoC-III-1500-del), the
promoter activities were markedly decreased (Fig. 3D). This indi-
cates that the activation of the apoC-III promoter by RXRa is at
least partly mediated through this DR-1 element. A similar element
also exists in the human promoter [11], whereas the overall pro-
moter sequences are not conserved between humans and mice.
The protein levels of RXRa during adipocyte differentiation
were also increased in 3T3-L1 cells, primary preadipocytes and
MEFs (Fig. 4A and data not shown). ChIP assays revealed that RXRa
binds to the promoter region, including the DR-1-like sequence, in
differentiated adipocytes, and that the binding was enhanced in
the presence of 9-cis RA (Fig. 4B). Consistent with the reported
RXR-dependent hepatic apoC-III gene expression [11], these results
clearly show that mouse gene expression in adipocytes is also reg-
ulated by RXRa.
Finally, it was found that the apoC-III gene expression in subcu-
taneous and epididymal fat was less than 1% but more than the
0.1% in liver and intestine, which are major organs expressing
abundant apoC-III (Fig. 5). These results suggest that the apoC-III
expressed in adipocytes functions within or at the periphery of
cells rather than acting on lipoprotein metabolism in the blood.
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